TuHURA Biosciences, Inc. (NASDAQ:HURA) Stock Rated “Moderate Buy” by Wall Street Brokerages

Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA) have been given an average rating of “Moderate Buy” by the six analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $9.00.

Several research firms recently issued reports on HURA. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, October 15th. Citizens Jmp reiterated a “market outperform” rating and set a $9.00 target price on shares of TuHURA Biosciences in a research report on Tuesday, August 18th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of TuHURA Biosciences in a research note on Tuesday, October 27th.

TuHURA Biosciences Stock Performance

Shares of HURA stock opened at $1.93 on Friday. The stock’s 50-day moving average price is $2.02 and its 200 day moving average price is $1.96. The company has a quick ratio of 0.18, a current ratio of 0.18 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $123.00 million, a PE ratio of -3.57 and a beta of -0.21. TuHURA Biosciences has a 52-week low of $0.41 and a 52-week high of $3.43.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. As a group, equities research analysts forecast that TuHURA Biosciences will post -0.57 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of HURA. BlackRock Inc. purchased a new position in TuHURA Biosciences in the 2nd quarter valued at approximately $1,615,000. Cetera Investment Advisers acquired a new position in TuHURA Biosciences during the first quarter worth $251,000. Bank of New York Mellon Corp purchased a new stake in TuHURA Biosciences during the second quarter worth $285,000. WealthShield Partners LLC purchased a new stake in TuHURA Biosciences during the first quarter worth $164,000. Finally, Invst LLC purchased a new stake in TuHURA Biosciences during the second quarter worth $99,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is directed toward treatments intended to address mechanisms that enable tumors to evade the immune system and resist existing cancer therapies.

TuHURA’s lead product candidate, IFx-2, is an investigational cancer immunotherapy designed for intratumoral administration. The program is intended to stimulate a broader anti-tumor immune response and potentially improve the effectiveness of immune checkpoint inhibitors and other established treatments.